Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juliana Souza Ribeiro Costa has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supramolecular Arrangement of Doxycycline with Sulfobutylether-β-Cyclodextrin: Impact on Nanostructuration with Chitosan, Drug Degradation and Antimicrobial Potency

    by Renata Carvalho Feitosa, Juliana Souza Ribeiro Costa, Marcelo van Vliet Lima, Elina Sawa Akioka Ishikawa, Karina Cogo Müller, Fernando Bonin Okasaki, Edvaldo Sabadini, Claudia Garnero, Marcela Raquel Longhi, Vladimir Lavayen, et al.

    Doxycycline (DX) is a well-established and broad-spectrum antimicrobial drug. However, DX has drawbacks, such as physicochemical instability in aqueous media and bacterial resistance. The inclusion of drugs in cyclodextrin complexes and their loading into nanocarriers can overcome these limitations. Thus, we studied the DX/sulfobutylether-β-CD (SBE-β-CD) inclusion complex for the first time and used it to reticulate chitosan. The resulting particles were evaluated by their physicochemical characteristics and antibacterial activity. DX/SBE-β-CD complexes were characterized by nuclear magnetic resonance, infrared spectroscopy, thermal analysis, X-ray diffraction, and scanning electron microscopy (SEM), whereas DX-loaded nanoparticles were characterized by dynamic light scattering, SEM, and drug content. The partial inclusion of the DX molecule in CD happened in a 1:1 proportion and brought increased stability to solid DX upon thermal degradation. Chitosan-complex nanoparticles measured approximately 200 nm, with a narrow polydispersity and particles with sufficient drug encapsulation for microbiological studies. Both formulations preserved the antimicrobial activity of DX against Staphylococcus aureus, whereas DX/SBE-β-CD inclusion complexes were also active against Klebsiella pneumoniae, indicating the potential use of these formulations as drug delivery systems to treat local infections.


  • Open Access

    Exploring Nanostructures for Doxycycline Delivery Based on Chitosan and Sulfobutylether-Β-Cyclodextrin

    by Renata Carvalho Feitosa, Juliana Souza Ribeiro Costa, Marcelo van Vliet Lima, Elina Sawa Akioka Ishikawa, Karina Cogo Müller, Fernando Bonin Okasaki, Edvaldo Sabadini, Claudia Garnero, Marcela Raquel Longhi, Vladimir Lavayen, et al.

    Doxycycline (DX) is a well-established and broad-spectrum antimicrobial drug. However, DX has drawbacks, such as physicochemical instability in aqueous media and bacterial resistance. It is known that the inclusion of drugs in cyclodextrin complexes and their loading in nanocarriers can overcome these limitations. Thus, we developed DX/sulfobutylether-β-CD (SBE-β-CD) inclusion complexes and DX-loaded nanoparticles, evaluating their physicochemical characteristics and antibacterial activity. DX/SBE-β-CD complexes were characterized by nuclear magnetic resonance, infrared spectroscopy, thermal analysis, X-ray diffraction and scanning electron microscopy (SEM), whereas DX-loaded nanoparticles were characterized by dynamic light scattering, SEM and drug content. Complexes and chitosan nanoparticles presented approximately 200 nm size, narrow polydispersity and particles with sufficient drug encapsulation (25%) for microbiological studies. Both formulations showed antimicrobial activity against Staphylococcus aureus, whereas DX/SBE-β-CD inclusion complexes were also active against Klebsiella pneumoniae , indicating the potential use of these formulations as drug delivery systems to treat local infections.

  • Sustainability of blisters for medicines in tablet form

    by Daniela Pedrosa de Oliveira, Juliana Souza Ribeiro Costa, Laura Oliveira-Nascimento


  • Open Access

    Capsaicin-Cyclodextrin Complex Enhances Mepivacaine Targeting and Improves Local Anesthesia in Inflamed Tissues

    by Verônica Muniz Couto, Laura de Oliveira-Nascimento, Luiz Fernando Cabeça, Danilo Costa Geraldes, Juliana Souza Ribeiro Costa, Karin A. Riske, Michelle Franz-Montan, Fabiano Yokaychiya, Margareth K. K. Dias Franco, Eneida de Paula

    Acidic environments, such as in inflamed tissues, favor the charged form of local anesthetics (LA). Hence, these drugs show less cell permeation and diminished potency. Since the analgesic capsaicin (CAP) triggers opening of the TRPV1 receptor pore, its combination with LAs could result in better uptake and improved anesthesia. We tested the above hypothesis and report here for the first time the analgesia effect of a two-drug combination (LA and CAP) on an inflamed tissue. First, CAP solubility increased up to 20 times with hydroxypropyl-beta-cyclodextrin (HP-β-CD), as shown by the phase solubility study. The resulting complex (HP-β-CD-CAP) showed 1:1 stoichiometry and high association constant, according to phase-solubility diagrams and isothermal titration calorimetry data. The inclusion complex formation was also confirmed and characterized by differential scanning calorimetry (DSC), X-ray diffraction, and 1H-NMR. The freeze-dried complex showed physicochemical stability for at least 12 months. To test in vivo performance, we used a pain model based on mouse paw edema. Results showed that 2% mepivacaine injection failed to anesthetize mice inflamed paw, but its combination with complexed CAP resulted in pain control up to 45 min. These promising results encourages deeper research of CAP as an adjuvant for anesthesia in inflamed tissues and cyclodextrin as a solubilizing agent for targeting molecules in drug delivery.


  • Open Access

    A mini-review on drug delivery through wafer technology: Formulation and manufacturing of buccal and oral lyophilizates

    by Juliana Souza Ribeiro Costa, Karen de Oliveira Cruvinel, Laura Oliveira-Nascimento


  • Open Access

    Pharmacokinetic Aspects of Nanoparticle-in-Matrix Drug Delivery Systems for Oral/Buccal Delivery

    by Renata Carvalho Feitosa, Danilo Costa Geraldes, Viviane Lucia Beraldo-De-Araújo, Juliana Souza Ribeiro Costa, Laura Oliveira-Nascimento

    Oral route maintains its predominance among the ones used for drug delivery, especially when medicines are self-administered. If the dosage form is solid, therapy gains in dose precision and drug stability. Yet, some active pharmaceutical substances do not present the required solubility, permeability or release profile for incorporation into traditional matrices. The combination of nanostructured drugs (NP) with these matrices is a new and little-explored alternative, which could bring several benefits. Therefore, this review focused on combined delivery systems based on nanostructures to administer drugs by the oral cavity, intended for buccal, sublingual, gastric or intestinal absorption. We analyzed published NP-in-matrix systems and compared main formulation characteristics, pharmacokinetics, release profiles and physicochemical stability improvements. The reported formulations are mainly semisolid or solid polymers, with polymeric or lipid nanoparticles and one active pharmaceutical ingredient. Regarding drug specifics, most of them are poorly permeable or greatly metabolized. The few studies with pharmacokinetics showed increased drug bioavailability and, sometimes, a controlled release rate. From our knowledge, the gathered data make up the first focused review of these trendy systems, which we believe will help to gain scientific deepness and future advancements in the field.


  • Open Access

    Excipient-excipient interactions in the development of nanocarriers: an innovative statistical approach for formulation decisions

    by Viviane Lucia Beraldo-De-Araújo, Anderson Beraldo-De-Araújo, Juliana Souza Ribeiro Costa, Ana Carolina Martins Pelegrine, Lígia Nunes Moraes Ribeiro, Eneida de Paula, Laura Oliveira-Nascimento

    Excipient interaction has become essential knowledge for rational formulation design of nanoparticles. Nanostructured lipid carriers (NLCs) include at least three types of excipient, which enhance excipient interaction possibilities and relevance. The present article introduces an alternative approach for evaluating a great number of excipients with few samples, using NLC as a model delivery system. This approach is based on two sequential experiments using Hall-2 experimental design and analysis of excipient interactions in respect to their physicochemical properties by multilevel statistics. NLCs were prepared using a hot emulsification-ultrasonication method with lidocaine and nine excipients (solid lipids, oils and surfactants). The evaluated parameters were z-average size (DLS), dispersity (DLS), zeta potential (electrophoretic mobility) and entrapment efficiency (HPLC). Cetyl palmitate, beeswax, castor oil, capric/caprylic acid and polysorbate 80 all presented larger effects amongst the studied factors as well as a clear pattern of synergistic interactions. Following the verified trends, we produced an optimized NLC that exhibited all desirable physicochemical characteristics and a modified drug release profile. Our results demonstrate the methodology’s robustness, which can be applied to other nanoparticles and establish a cost-effective excipient evaluation.


  • Open Access

    Biodegradable nanocarriers coated with polymyxin B: Evaluation of leishmanicidal and antibacterial potential

    by Juliana Souza Ribeiro Costa, Marília Medeiros, Edite Harumi Yamashiro-Kanashiro, Mussya Cisotto Rocha, Paulo Cesar Cotrim, Marco Antonio Stephano, Marcelo Lancellotti, Guilherme Diniz Tavares, Laura Oliveira-Nascimento

    Most treatments of leishmaniasis require hospitalization and present side effects or parasite resistance; innovations in drug formulation/reposition can overcome these barriers and must be pursued to increase therapeutic alternatives. Therefore, we tested polymyxin B (polB) potential to kill Leishmania amazonensis, adsorbed or not in PBCA nanoparticles (PBCAnp), which could augment polB internalization in infected macrophages. PBCAnps were fabricated by anionic polymerization and analyzed by Dynamic Light Scattering (size, ζ potential), Nanoparticle Tracking Analysis (size/concentration), vertical diffusion cell (release rate), drug incorporation (indirect method, protein determination) and in vitro cell viability. Nanoparticles coated with polB (PBCAnp-polB) presented an adequate size of 261.5 ± 25.9 nm, low PDI and ζ of 1.79 ± 0.17 mV (stable for 45 days, at least). The 50% drug release from PBCAnp-polB was 6–7 times slower than the free polB, which favors a prolonged and desired release profile. Concerning in vitro evaluations, polB alone reduced in vitro amastigote infection of macrophages (10 μg/mL) without complete parasite elimination, even at higher concentrations. This behavior limits its future application to adjuvant leishmanicidal therapy or antimicrobial coating of carriers. The nanocarrier PBCAnp also presented leishmanicidal effect and surpassed polB activity; however, no antimicrobial activity was detected. PolB maintained its activity against E. coli, Pseudomonas and Klebsiella, adding antimicrobial properties to the nanoparticles. Thus, this coated drug delivery system, described for the first time, demonstrated antileishmanial and antimicrobial properties. The bactericidal feature helps with concomitant prevention/treatment of secondary infections that worst ulcers induced by cutaneous L. amazonensis, ultimately ending in disfiguring or disabling lesions. Cutaneous leishmaniasis form disfiguring lesions that leads to depression and social isolation. Both consequences result often in economic and education loss for communities already short on resources. The actual treatment aims to eliminate the protozoa disease-vector. Yet, it presents undesired effects or parasite resistance, besides the need for intravenous infusions and hospitalization. There is a few topical leishmanicidals but none with prolonged action. As highlighted, no ideal therapy exists; we must keep searching for alternatives, which includes new drugs, vehicles or therapies. For drugs, the most cost-effective way comprises testing approved molecules for other diseases, such as the antimicrobial polymyxin B (polB). Repositioning a drug has the added benefit of known safety profile and drawbacks, shortening and narrowing the research path. In turn, carriers can decrease side-effects and multiple dosing. They shield and/or improve drug targeting, which in this case means delivering inside macrophages infected with Leishmania. An example is poly (n-butyl cyanoacrylate) nanoparticles (PBCAnp), shown as an efficient carrier for targeting an extended drug release. Therefore, this work aimed to evaluate leishmanicidal and adjuvant properties of polB, alone and absorbed onto PBCAnp.


  • Polymeric nanocarriers for polymyxin B delivery

    by Luiza Samira Da Silva Lazaro, Laura De Oliveira Nascimento, Juliana Souza Ribeiro Costa